Stockscreener 앱 받기
69.59
3.90%
2.61
시간 외 거래:
68.70
-0.89
-1.28%
전일 마감가:
$66.98
열려 있는:
$70.08
하루 거래량:
8.94M
Relative Volume:
2.95
시가총액:
$13.17B
수익:
$2.83B
순이익/손실:
$-1.02B
주가수익비율:
-12.63
EPS:
-5.51
순현금흐름:
$194.14M
1주 성능:
+9.94%
1개월 성능:
+22.69%
6개월 성능:
+35.00%
1년 성능:
-2.17%
1일 변동 폭
$67.61
$72.81
1주일 범위
$62.54
$72.81
52주 변동 폭
$38.81
$72.83
이그젝트 사이 Stock (EXAS) Company Profile
명칭
Exact Sciences Corp
전화
608-284-5700
주소
5505 ENDEAVOR LANE, MADISON, WI
EXAS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
69.59 | 12.68B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
565.24 | 212.23B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
213.83 | 151.20B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
722.12 | 57.84B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
146.08 | 41.02B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
210.96 | 36.42B | 15.90B | 1.28B | 2.21B | 7.2842 |
이그젝트 사이 Stock (EXAS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-27 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-01-02 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-10-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-08-02 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-05-10 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2023-05-05 | 개시 | UBS | Neutral |
| 2023-03-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-02-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-06-03 | 개시 | Piper Sandler | Neutral |
| 2021-11-03 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | 재확인 | BTIG Research | Buy |
| 2021-07-29 | 재확인 | Canaccord Genuity | Buy |
| 2021-07-29 | 재확인 | Oppenheimer | Outperform |
| 2021-07-29 | 재확인 | Stifel | Buy |
| 2021-06-15 | 개시 | Raymond James | Strong Buy |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-05-25 | 개시 | Wells Fargo | Equal Weight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-29 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-10-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-08 | 재개 | BTIG Research | Buy |
| 2020-04-02 | 개시 | Evercore ISI | Outperform |
| 2020-01-10 | 재개 | BTIG Research | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Dougherty & Company | Buy |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-10-17 | 재확인 | BofA/Merrill | Buy |
| 2019-10-01 | 재개 | Craig Hallum | Buy |
| 2019-09-26 | 개시 | Oppenheimer | Outperform |
| 2019-02-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-09 | 개시 | UBS | Buy |
| 2018-09-05 | 재개 | The Benchmark Company | Hold |
| 2018-08-13 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2018-01-29 | 개시 | Goldman | Neutral |
| 2018-01-08 | 재확인 | The Benchmark Company | Buy |
| 2017-11-13 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | 다운그레이드 | BTIG Research | Buy → Neutral |
모두보기
이그젝트 사이 주식(EXAS)의 최신 뉴스
Key facts: Exact Sciences Q3 Revenue Hits $850.7M; Cancerguard Launched; Analysts Raise Price Targets - TradingView
EXAS: TD Cowen Raises Price Target to $90 on Buy Rating | EXAS S - GuruFocus
Exact Sciences (EXAS) Receives Updated Analyst Rating from Baird - GuruFocus
EXAS: Benchmark Raises Price Target to $75 in Latest Analyst Rev - GuruFocus
EXAS: Guggenheim Raises Price Target to $75 While Maintaining Bu - GuruFocus
Stifel raises Exact Sciences stock price target to $80 on strong Cologuard growth - Investing.com
EXAS: Barclays Raises Price Target to $77, Maintains Overweight Rating | EXAS Stock News - GuruFocus
These Analysts Raise Their Forecasts On Exact Sciences Following Better-Than-Expected Q3 Results - Benzinga
Madison-based Exact Sciences reports Q3 results topping analysts’ expectations - Wisconsin State Journal
EXAS Q3 Deep Dive: Cologuard Plus, Care Gap Programs, and New Test Launches Drive Growth - Yahoo! Finance Canada
EXAS: Stifel Raises Target Price to $80, Maintains Buy Rating | - GuruFocus
Can Exact Sciences Corporation (EXK) stock stage a strong rebound this quarterJuly 2025 Trade Ideas & Proven Capital Preservation Methods - newser.com
BTIG Raises Price Target for Exact Sciences (EXAS) to $85 | EXAS Stock News - GuruFocus
Exact Sciences stock price target raised to $85 from $75 at BTIG - Investing.com
Exact Sciences to Participate in November Investor Conference - Bluefield Daily Telegraph
How Intuitive Surgical Stock Gained 19.5% Last Month - AOL.com
Exact Sciences Corporation stock chart pattern explained2025 AllTime Highs & Daily Profit Focused Screening - newser.com
Exact Sciences: Q3 Earnings Snapshot - New Haven Register
Canaccord Genuity raises Exact Sciences stock price target to $85 on strong growth - Investing.com
Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight - GuruFocus
Exact Sciences Corp (EXAS) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Exact Sciences Reports Record Q3 Revenue and Raises Guidance - TipRanks
Transcript : Exact Sciences Corporation, Q3 2025 Earnings Call, Nov 03, 2025 - MarketScreener
Exact Sciences Q3 2025 slides: 20% revenue growth, guidance raised - Investing.com
Earnings call transcript: Exact Sciences beats Q3 2025 EPS forecasts - Investing.com
EXACT SCIENCES CORP SEC 10-Q Report - TradingView
Exact Sciences Corp (EXAS) Q3 2025 Earnings: Revenue Surpasses E - GuruFocus
Exact Sciences stock higher after beating Q3 expectations, raising guidance By Investing.com - Investing.com South Africa
Exact Sciences Announces Third Quarter 2025 Results - Stock Titan
What candlestick patterns are forming on Exact Sciences CorporationGlobal Markets & Entry Point Confirmation Signals - newser.com
Exact Sciences (EXAS) Q3 Earnings Preview: Positive Revisions Bo - GuruFocus
Exact Sciences Corporation Stock (EXAS) Opinions on Upcoming Earnings and Clinical Data - Quiver Quantitative
Should You Buy Exact Sciences Stock Before Nov. 3? - MSN
Nisa Investment Advisors LLC Acquires 4,500 Shares of Exact Sciences Corporation $EXAS - MarketBeat
How New Developments Are Shaping the Analyst Story for Exact Sciences - Yahoo Finance
Exact Sciences (EXAS) Reports Q3: Everything You Need To Know Ahead Of Earnings - Yahoo! Finance UK
Exact Sciences Corporation (EXAS) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
EXACT SCIENCES Earnings Preview: Recent $EXAS Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Exact Sciences Corporation $EXAS Shares Sold by Jennison Associates LLC - MarketBeat
Brighton Jones LLC Takes $366,000 Position in Exact Sciences Corporation $EXAS - MarketBeat
KLCM Advisors Inc. Invests $212,000 in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences pulls out of major expansion project near Phoenix Sky Harbor - azcentral.com and The Arizona Republic
Exact Sciences’ MCED Test Study: A Potential Game-Changer in Early Cancer Detection - MSN
Exact Sciences’ Latest Study on Breast Cancer Recurrence Detection: A Potential Game Changer - MSN
69,932 Shares in Exact Sciences Corporation $EXAS Acquired by Y Intercept Hong Kong Ltd - MarketBeat
Why Exact Sciences Corporation stock could see breakout soon2025 Market Trends & Expert Curated Trade Ideas - newser.com
Can Exact Sciences Corporation (EXK) stock hit consensus price targetsWeekly Trend Report & Accurate Intraday Trading Signals - newser.com
One-on-One with David Harding of Exact Sciences - Modern Healthcare
A Look at Exact Sciences’s Valuation as New Cancer Screening Advances Debut at Major Gastroenterology Meeting - Yahoo Finance
Zanotti of Exact Sciences sells $780k in stock By Investing.com - Investing.com UK
Leading vs lagging indicators on Exact Sciences Corporation performance2025 Performance Recap & Real-Time Chart Breakout Alerts - newser.com
이그젝트 사이 (EXAS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.45%
6.29%
자본화:
|
볼륨(24시간):